Vladimir Bantseev1, Paul E Miller2,3, T Michael Nork3,4, Carol A Rasmussen3,4, Aija McKenzie1, Brian J Christian5, Helen Booler1, Evan A Thackaberry1. 1. 1 Genentech, Inc., Department of Safety Assessment, South San Francisco, California. 2. 2 Department of Surgical Services, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin. 3. 3 Ocular Services on Demand, LLC (OSOD), Madison, Wisconsin. 4. 4 Department of Ophthalmology and Visual Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin. 5. 5 Covance Laboratories, Inc., Madison, Wisconsin.
Abstract
Purpose: To characterize the inflammatory response and determine the no-observable-effect level (NOEL) in cynomolgus monkey eyes after intravitreal (ITV) injection of endotoxin. Methods: The inflammatory response to endotoxin was assessed in a single-dose study in monkeys at doses of 0.01 to 0.51 endotoxin units (EU)/eye. Tolerability was assessed by clinical ophthalmic examinations, intraocular pressure measurements, fundus color photography, optical coherence tomography, and anatomic pathology. Results: ITV injection of endotoxin at ≥0.04 EU/eye resulted in a dose-related anterior segment inflammatory response. No aqueous flare or cell was noted in the 0.01 EU/eye dose group. A more delayed posterior segment response characterized by vitreous cell was observed beginning on day 5, peaking on day 15, and decreasing in some groups. Microscopic findings of mononuclear cell infiltrates in the vitreous were observed in eyes given ≥0.21 EU/eye. Conclusion: The NOEL for ITV endotoxin in cynomolgus monkeys was 0.01 EU/eye, suggesting that this species is as sensitive as rabbits to the effects of endotoxin. The vitreous cavity also appears more sensitive to endotoxin than the anterior segment/aqueous chamber. Overall, the magnitude of the inflammatory response at ≥0.04 EU/eye suggests that dose-response curve in monkeys is steeper than in rabbits. These data highlight the importance of assessing endotoxin level in ITV formulations, as levels as low as 0.04 EU/eye may confound the safety evaluations of ITV therapeutics in cynomolgus monkeys.
Purpose: To characterize the inflammatory response and determine the no-observable-effect level (NOEL) in cynomolgus monkey eyes after intravitreal (ITV) injection of endotoxin. Methods: The inflammatory response to endotoxin was assessed in a single-dose study in monkeys at doses of 0.01 to 0.51 endotoxin units (EU)/eye. Tolerability was assessed by clinical ophthalmic examinations, intraocular pressure measurements, fundus color photography, optical coherence tomography, and anatomic pathology. Results: ITV injection of endotoxin at ≥0.04 EU/eye resulted in a dose-related anterior segment inflammatory response. No aqueous flare or cell was noted in the 0.01 EU/eye dose group. A more delayed posterior segment response characterized by vitreous cell was observed beginning on day 5, peaking on day 15, and decreasing in some groups. Microscopic findings of mononuclear cell infiltrates in the vitreous were observed in eyes given ≥0.21 EU/eye. Conclusion: The NOEL for ITV endotoxin in cynomolgus monkeys was 0.01 EU/eye, suggesting that this species is as sensitive as rabbits to the effects of endotoxin. The vitreous cavity also appears more sensitive to endotoxin than the anterior segment/aqueous chamber. Overall, the magnitude of the inflammatory response at ≥0.04 EU/eye suggests that dose-response curve in monkeys is steeper than in rabbits. These data highlight the importance of assessing endotoxin level in ITV formulations, as levels as low as 0.04 EU/eye may confound the safety evaluations of ITV therapeutics in cynomolgus monkeys.
Entities:
Keywords:
drug development; endotoxin; intravitreal injection; ocular toxicology
Authors: Preeta K Kutty; Terri S Forster; Carol Wood-Koob; Nancy Thayer; Robert B Nelson; Stanley J Berke; Lillian Pontacolone; Thomas L Beardsley; Henry F Edelhauser; Matthew J Arduino; Nick Mamalis; Arjun Srinivasan Journal: J Cataract Refract Surg Date: 2008-04 Impact factor: 3.351
Authors: Robert B Nussenblatt; Don Calogero; Shelley Y Buchen; Henry A Leder; Margot Goodkin; Malvina B Eydelman Journal: Ophthalmology Date: 2012-05-11 Impact factor: 12.079
Authors: Peter M Maloca; Christine Seeger; Helen Booler; Philippe Valmaggia; Ken Kawamoto; Qayim Kaba; Nadja Inglin; Konstantinos Balaskas; Catherine Egan; Adnan Tufail; Hendrik P N Scholl; Pascal W Hasler; Nora Denk Journal: Sci Rep Date: 2021-10-19 Impact factor: 4.379
Authors: Tatiana M Corey; Vernard V Woodley; Merissa O'Connor; Emma Connolly; Sarah Doyle; Stephanie Shrader; Cyrene Phipps; Kimicia Isaac; Matthew Lawrence Journal: Transl Vis Sci Technol Date: 2022-08-01 Impact factor: 3.048